HomeAI · summaries
Storia in 3 fonti
Cipla partners with Qilu Pharmaceutical for Keytruda biosimilar in US
Cipla’s wholly owned US subsidiary Invagen Pharmaceuticals has partnered with Qilu Pharmaceutical to license and supply QL2107, a pembrolizumab biosimilar, for marketing in the United States.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Cipla partners with Qilu Pharmaceutical for Keytruda biosimilar in US
Cipla’s wholly owned US subsidiary Invagen Pharmaceuticals has partnered with Qilu Pharmaceutical to license and supply QL2107, a pembrolizumab biosimilar, for marketing in the…
- ·
economictimes.indiatimes.com
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Cipla said its US unit has entered an exclusive partnership with Chinas Qilu Pharmaceutical to license QL2107, a biosimilar of Mercks cancer drug Keytruda. Qilu will handle…
